Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Olutasidenib→

Olutasidenib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1887014-12-1
Molecular formula
C18H15ClN4O2
Molecular weight
354.79 g/mol
Drug class
Mutant isocitrate dehydrogenase-1 (IDH1) inhibitortargeted antineoplastic
Mechanism of action
Inhibits mutant IDH1 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate. This promotes differentiation of leukaemic myeloid cells and reduces the abnormal epigenetic signalling driven by mutant IDH1.
Indications / reported uses
  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible IDH1 mutation detected by an FDA-approved test; specialist haematology use

Sources: US DailyMed — REZLIDHIA (olutasidenib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Olutasidenib Environmental Risk Assessment (ERA) (the Olutasidenib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.